2.1. Oral analgesics
2.1.1. What are the benefits and harms of paracetamol in the management of patients with hip OA?
2.1.2. What are the benefits and harms of oral NSAIDs including COX-2 inhibitors in the management of patients with hip OA?
2.1.3. What are the benefits and harms of oral opioids in the management of patients with hip OA?
2.2. Topical analgesics
2.2.1. What are the benefits and harms of topical NSAIDs in the management of patients with hip OA?
2.2.2. What are the benefits and harms of transdermal opioids in the management of patients with hip OA?
2.2.3. What are the benefits and harms of topical capsaicin in the management of patients with hip OA?
2.3. Herbal therapies
2.3.1. What are the benefits and harms of ASU in the management of patients with hip OA?
2.3.2. What are the benefits and harms of Boswellia serrata in the management of patients with hip OA?
2.3.3. What are the benefits and harms of curcuma in the management of patients with hip OA?
2.3.4. What are the benefits and harms of pycnogenol in the management of patients with hip OA?
2.4. Nutraceuticals
2.4.1. What are the benefits and harms of glucosamine in the management of patients with hip OA?
2.4.2. What are the benefits and harms of chondroitin in the management of patients with hip OA?
2.4.3. What are the benefits and harms of glucosamine and chondroitin in compound form in the management of patients with hip OA?
2.4.4. What are the benefits and harms of vitamin D in the management of patients with hip OA?
2.4.5. What are the benefits and harms of (omega-3/6) poly-unsaturated fatty acids in the management of patients with hip OA?
2.4.6. What are the benefits and harms of collagen preparations in the management of patients with hip OA?
2.4.7. What are the benefits and harms of methylsulfonylmethane (MSM) in the management of patients with hip OA?
2.4.8. What are the benefits and harms of diacerein in the management of patients with hip OA?
2.5. What are the benefits and harms of duloxetine in the management of patients with hip OA?
2.6. What are the benefits and harms of doxycycline in the management of patients with hip OA?
2.7. Anti-osteoporosis (anti-resorptive bone-acting) drugs
2.7.1. What are the benefits and harms of bisphosphonates in the management of patients with hip OA?
2.7.2. What are the benefits and harms of calcitonin in the management of patients with hip OA? 2.7.3. What are the benefits and harms of strontium ranelate in the management of patients with hip OA?
2.8. Investigational DMOADs (symptomatic or inflammatory modification)
2.8.1. What are the benefits and harms of IL-1 inhibitors in the management of patients with hip OA?
2.8.2. What are the benefits and harms of TNF-alpha inhibitors in the management of patients with hip OA?
2.8.3. What are the benefits and harms of anti-NGF therapy in the management of patients with hip OA?
2.8.4. What are the benefits and harms of FGF therapy in the management of patients with hip OA?
2.8.5. What are the benefits and harms of colchicine in the management of patients with hip OA?
2.8.6. What are the benefits and harms of methotrexate in the management of patients with hip OA?
2.8.7. What are the benefits and harms of statins in the management of patients with hip OA? - excluded
2.9. Intra-articular injections
2.9.1. What are the benefits and harms of corticosteroids in the management of patients with hip OA?
2.9.2. What are the benefits and harms of viscosupplementation in the management of patients with hip OA?
2.9.3. What are the benefits and harms of PRP in the management of patients with hip OA?
2.9.4. What are the benefits and harms of stem cell therapy in the management of patients with hip OA?
2.9.5. What are the benefits and harms of dextrose prolotherapy in the management of patients with hip OA?